echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Researchers have discovered important links between Alzheimer's disease, cancer and COVID-19

    Researchers have discovered important links between Alzheimer's disease, cancer and COVID-19

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     

    Vanderbilt University Medical Center (Vanderbilt University Medical Center) researchers discovered a kind of nanoparticles released from cells, called "super particles", which contain enzymes, proteins and RNA, and a variety of cancer, cardiovascular diseases , Alzheimer’s disease and even COVID-19


    This discovery was published in the journal Nature Cell Biology on December 9, 2021.


    The senior author of the paper Robert Coffey, MD, said: "We have discovered some biomarkers and therapeutic targets in cancer and many other disease states, and these biomarkers and therapeutic targets may be the carriers of these super particles


    The author of this article, Professor Coffey of Medicine and Cell and Developmental Biology, is well known for his research on colorectal cancer



    (Front row from left) Dr.


    (Back row from left) Dr.


    In 2019, Dr.


    That year, another colleague of Coffey, Dr.


    In the current study, Zhang took the "supernatant", which is the liquid that remains after the exopolymer is rotated into "particles," and centrifuged the liquid faster and longer


    The result is nanoparticles separated from the supernatant of the spinning exosomes, which the researchers named supermeres


    First, supermeres carry extracellular RNA released by most cells, and these RNAs are present in the blood


    Supermeres are important carriers of TGFBI, which is a protein that promotes tumor progression in established tumors


    They also carry ACE2, a cell surface receptor that plays a role in cardiovascular disease and the target of the COVID-19 virus


    Another important cargo is APP, an amyloid beta precursor protein that is involved in the development of Alzheimer's disease


    Researchers from the University of Notre Dame pointed out in a review article published with this paper: “Identified such a wealth of bioactive molecules.


    Reference: "Supermeres are functional extracellular nanoparticles replete with disease biomarkers and therapeutic targets" by Qin Zhang, Dennis K.
    Jeppesen, James N.
    Higginbotham, Ramona Graves-Deal, Vincent Q.
    Trinh, Marisol A.
    Ramirez, Yoojin Sohn, Abigail C Neininger, Nilay Taneja, Eliot T.
    McKinley, Hiroaki Niitsu, Zheng Cao, Rachel Evans, Sarah E.
    Glass, Kevin C.
    Ray, William H.
    Fissell, Salisha Hill, Kristie Lindsey Rose, Won Jae Huh, Mary Kay Washington, Gregory Daniel Ayers, Dylan T.
    Burnette, Shivani Sharma, Leonard H.
    Rome, Jeffrey L.
    Franklin, Youngmin A.
    Lee, Qi Liu and Robert J.
    Coffey, 9 December 2021, Nature Cell Biology .

    DOI: 10.
    1038/s41556-021 -00805-8

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.